JP Morgan: Brandicourt Signals M&A Interest To Boost Sanofi's Growth
This article was originally published in Scrip
Executive Summary
Olivier Brandicourt had a lot to say at his first JP Morgan as Sanofi CEO. With plans to deliver on an "underappreciated" vaccine portfolio, ambitions to "double revenues" from the multiple sclerosis franchise, and a "rebuilding" of the oncology pipeline through M&A, Scrip is enjoying Brandicourt's energy.
You may also be interested in...
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.